Related references
Note: Only part of the references are listed.Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors:: two year results from the RIO-Europe Study
Luc F. Van Gaal et al.
EUROPEAN HEART JOURNAL (2008)
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease -: The STRADIVARIUS randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Endocannabinoid control of food intake and energy balance
V Di Marzo et al.
NATURE NEUROSCIENCE (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Share Paper
